Effect of proton-pump inhibitor therapy on serum chromogranin a level

Digestion. 2011;84(1):22-8. doi: 10.1159/000321535. Epub 2011 Feb 8.


Background: The neuroendocrine marker, chromogranin A (CgA) increases during medium- or long-term proton-pump inhibitor (PPI) treatment.

Aims: To analyze the effect of ultra-short-term and diverse dose of PPI therapy on serum CgA and gastrin levels and evaluate the effect of PPI treatment cessation.

Patients and methods: Fasting serum CgA and gastrin were determined in newly diagnosed gastroesophageal reflux disease (GERD) patients (n = 54) treated with diverse doses of PPI during a 28-day period, in patients treated with PPIs for at least 6 months (n = 42), and in subjects where PPI treatment could be stopped (n = 11).

Results: A significant stepwise increase of CgA levels was observed after 5 days during the 28-day period treatment with all PPI doses. Gastrin increased significantly also in the standard and high-dose PPI subgroups. The most prominent increase of CgA was observed in the high-dose PPI subgroup. Serum CgA and gastrin were markedly elevated after 6 months of PPI treatment, and decreased significantly after 5 days of PPI discontinuation.

Conclusions: Serum CgA increases significantly even after ultra-short-term (5 days) PPI therapy. After long-term treatment, 5-day cessation of PPI therapy is sufficient to decrease significantly both CgA and gastrin levels.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chromogranin A / blood*
  • Chromogranin A / drug effects
  • Female
  • Gastrins / blood*
  • Gastrins / drug effects
  • Gastroesophageal Reflux / blood
  • Gastroesophageal Reflux / drug therapy*
  • Gastroesophageal Reflux / microbiology
  • Helicobacter Infections / blood
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Proton Pump Inhibitors / administration & dosage*
  • Time Factors
  • Young Adult


  • Chromogranin A
  • Gastrins
  • Proton Pump Inhibitors